Companion Diagnostics for Cancer and Autoimmune Drugs

Sengenics has an extensive track record of working with academic and pharmaceutical collaborators to discover novel autoantibody signatures for autoimmune disease and cancer immunotherapy drugs. These signatures usually consist of a relatively low number of biomarkers that have high sensitivity and specificity, making the results highly amenable to be converted into a low-cost companion diagnostic.

Key benefits and uses

  • identify patients who are most likely to benefit from a particular drug;
  • identify patients who are more likely to be at increased risk for developing serious ADRs;
  • monitor response to drugs in order to adjust dosage or treatment regimes to achieve improved safety and/or efficacy.


IMMUNOME Protein Array

High-throughput autoantibody screening protein array containing 1600+ autoantigens


Contains correctly folded antigens from SARS-CoV-2 and 25 other Corona and Influenza viruses

SEROMAX Blood Collection Kit

Obviates conventional blood draw and cold chain by only requiring a pin-prick of blood

Sengenics - Functional Proteomics | Krex Technology | Protein Array Supplier

Sengenics is a functional proteomics company that leverages its patented KREX technology for production of full-length, correctly folded and functional proteins. The key application of KREX is the discovery of autoantibody biomarkers for two core medical use cases:  stratification of patients undergoing treatment with autoimmune or cancer drugs and identification of autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

Find Us On:

© 2008 – 2021 Sengenics All rights reserved | Sengenics Corporation Pte Ltd. Registered in Singapore no. 201734100D | Sengenics UK Ltd. Registered in England and Wales No 11016361